RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Karyopharm Therapeutics (NASDAQ:KPTI), but lowered the price target from $5 to $4.
August 04, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has maintained an 'Outperform' rating on Karyopharm Therapeutics but lowered the price target from $5 to $4.
The news is directly related to Karyopharm Therapeutics. While the 'Outperform' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100